|
Demographic features
|
Value
|
|
Male/female, n
|
6/78
|
|
Mean age ± SD (years)
|
41.3 ± 12.2
|
|
Mean disease duration ± SD (months)
|
142.1 ± 103.8
|
|
Clinical manifestations, n (%)
|
|
Joint involvement
|
57 (67.8)
|
|
Skin involvement
|
58 (69.0)
|
|
Serositis
|
18 (21.4)
|
|
Hematological manifestations
|
37 (44.0)
|
|
Neuropsychiatric involvement
|
10 (11.9)
|
|
Renal involvement
|
31 (36.9)
|
|
Laboratory manifestations, n (%)
|
|
Antinuclear antibodies
|
84 (100.0)
|
|
Anti-DNA
|
69 (82.1)
|
|
Anti-Sm
|
13 (15.5)
|
|
Anti-SSA
|
24 (28.6)
|
|
Anti-SSB
|
10 (11.9)
|
|
Anti-RNP
|
10 (11.9)
|
|
Anti-cardiolipin IgG/IgM
|
30 (35.7)
|
|
Anti-β2Glicoprotein I IgG/IgM
|
8 (9.5)
|
|
Lupus anticoagulant
|
12 (14.3)
|
|
Low C3 levels
|
32 (38.1)
|
|
Low C4 levels
|
44 (52.4)
|
|
Treatments, n (%)
|
|
Corticosteroids
|
60 (71.4)
|
|
Hydroxychloroquine
|
54 (64.3)
|
|
Cyclosporine A
|
19 (22.6)
|
|
Methotrexate
|
17 (20.2)
|
|
Cyclophosphamide
|
19 (22.6)
|
|
Mycophenolate mofetil
|
15 (17.8)
|
|
Azathioprine
|
18 (21.4)
|
|
ASA
|
25 (29.7)
|
|
Anticoagulant therapy
|
9 (10.7)
|
